N
Noopur Raje
Researcher at Harvard University
Publications - 557
Citations - 32974
Noopur Raje is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 82, co-authored 506 publications receiving 27878 citations. Previous affiliations of Noopur Raje include Brigham and Women's Hospital & Indiana University.
Papers
More filters
Journal ArticleDOI
Multiple myeloma
Noopur Raje,Kenneth C. Anderson +1 more
TL;DR: The use of bisphosphonates in patients with multiple myeloma (MM) has clearly demonstrated benefit and reduced morbidity associated with bone disease, but all patients with MM ultimately relapse and succumb to their disease.
Journal ArticleDOI
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman,Igor Puzanov,Vivek Subbiah,Jason E. Faris,Ian Chau,Jean-Yves Blay,Juergen Wolf,Noopur Raje,Eli L. Diamond,Antoine Hollebecque,Radj Gervais,Maria Elena Elez-Fernandez,Antoine Italiano,Ralf-Dieter Hofheinz,Manuel Hidalgo,Emily Chan,Martin Schuler,Susan Frances Lasserre,Martina Makrutzki,Florin Sirzen,Maria Luisa Veronese,Josep Tabernero,José Baselga +22 more
TL;DR: BRAF V600 appears to be a targetable oncogene in some, but not all, nonmelanoma cancers and preliminary vemurafenib activity was observed in non-small-cell lung cancer and in Erdheim-Chester disease and Langerhans'-cell histiocytosis.
Journal ArticleDOI
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
Noopur Raje,Jesus G. Berdeja,Yi Lin,David S. Siegel,Sundar Jagannath,Deepu Madduri,Michaela Liedtke,Jacalyn Rosenblatt,Marcela V. Maus,Ashley Turka,Lyh Ping Lam,Richard A. Morgan,Kevin G. Friedman,Monica Massaro,Julie Wang,Greg Russotti,Zhihong Yang,Timothy B. Campbell,Kristen Hege,Fabio Petrocca,M. Travis Quigley,Nikhil C. Munshi,James N. Kochenderfer +22 more
TL;DR: The initial toxicity profile of a BCMA‐directed cellular immunotherapy for patients with relapsed or refractory multiple myeloma is reported andCAR T‐cell expansion was associated with responses, and CAR T cells persisted up to 1 year after the infusion.
Journal ArticleDOI
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Faith E. Davies,Noopur Raje,Noopur Raje,Noopur Raje,Teru Hideshima,Teru Hideshima,Teru Hideshima,Suzanne Lentzsch,Suzanne Lentzsch,Suzanne Lentzsch,Gloria Young,Gloria Young,Gloria Young,Yu-Tzu Tai,Yu-Tzu Tai,Yu-Tzu Tai,Boris Lin,Boris Lin,Boris Lin,Klaus Podar,Klaus Podar,Klaus Podar,Deepak K. Gupta,Deepak K. Gupta,Deepak K. Gupta,Dharminder Chauhan,Dharminder Chauhan,Dharminder Chauhan,Steven P. Treon,Steven P. Treon,Steven P. Treon,Paul G. Richardson,Paul G. Richardson,Paul G. Richardson,Robert L. Schlossman,Robert L. Schlossman,Robert L. Schlossman,Gareth J. Morgan,Gareth J. Morgan,Gareth J. Morgan,George W. Muller,George W. Muller,George W. Muller,David I. Stirling,David I. Stirling,David I. Stirling,Kenneth C. Anderson,Kenneth C. Anderson,Kenneth C. Anderson +48 more
TL;DR: In vitro and in vivo data support the hypothesis that Thal may mediate its anti-MM effect, at least in part, by modulating NK cell number and function.
Journal ArticleDOI
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Teru Hideshima,Dharminder Chauhan,Dharminder Chauhan,Yoshihito Shima,Yoshihito Shima,Noopur Raje,Noopur Raje,Faith E. Davies,Faith E. Davies,Yu-Tzu Tai,Yu-Tzu Tai,Steven P. Treon,Steven P. Treon,Boris Lin,Boris Lin,Robert L. Schlossman,Robert L. Schlossman,Paul G. Richardson,Paul G. Richardson,George W. Muller,George W. Muller,David I. Stirling,David I. Stirling,Kenneth C. Anderson,Kenneth C. Anderson +24 more
TL;DR: Clinical activity of Thal against MM that is refractory to conventional therapy is demonstrated and mechanisms of anti-tumor activity of thalidomide and its potent analogs (immunomodulatory drugs [IMiDs]) are delineated.